ERIC JONASCH to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications ERIC JONASCH has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.254
-
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev. 2020 Sep; 89:102062.
Score: 0.150
-
Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol. 2011 Nov; 7(11):1247-53.
Score: 0.082
-
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3961-3971.
Score: 0.021